Drugs / US-Keytruda®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07180862 Comparator | Oct 2025 → Feb 2027 expected | non-small cell lung carcinoma | Bio-Thera Solutions | Recruiting | No outcome recorded |
| Phase 3 | NCT06280196 Comparator | Jul 2024 → Jul 2025 | non-small cell lung carcinoma | Bio-Thera Solutions | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | US-Keytruda | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06280196 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT07180862 ↗ |